Kevin Meier: Important Nuance in the 2026 AHA/ACC Acute PE Guideline for Patients with Brain Tumors
Kevin Meier, Neurointensivist at Intermountain Medical Center, shared a post on LinkedIn about a recent article by Mark A. Creager et al, adding:
“The 2026 AHA/ACC acute PE guideline added an important nuance for patients with brain tumors and acute PE.
In patients with primary or metastatic brain tumors who are otherwise eligible for oral anticoagulation, a DOAC may be considered over LMWH to reduce ICH risk.
The recommendation is weak, Class 2b, Level C-LD, but it is now explicit in a major PE guideline.
Important caveat: this is not high-level trial evidence.
The signal comes from retrospective observational data, and the apparent ICH advantage of DOACs is clearest in primary brain tumors.
For metastatic brain tumors, the pooled data are more neutral or mixed than definitive.
Separate point: pooled data suggest anticoagulation increases ICH risk in primary brain cancer but not clearly in metastatic disease, even though metastatic tumors carry higher background ICH risk overall.
So this doesn’t make DOACs a universal answer, but it does mean the old LMWH-first reflex deserves another look.”
Title: 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Authors: Mark A. Creager, Geoffrey D. Barnes, Jay Giri, Debabrata Mukherjee, William Schuyler Jones, Allison E. Burnett, Teresa Carman, Ana I. Casanegra, Lana A. Castellucci, Sherrell M. Clark, Mary Cushman, Kerstin de Wit, Jennifer M. Eaves, Margaret C. Fang, Joshua B. Goldberg, Stanislav Henkin, Hillary Johnston-Cox, Sabeeda Kadavath, Daniella Kadian-Dodov, William Brent Keeling, Andrew J.P. Klein, Jun Li, Michael C. McDaniel, Lisa K. Moores, Gregory Piazza, Karen S. Prenger, MS, Steven C. Pugliese, Mona Ranade, Rachel P. Rosovsky, Farla Russo, Eric A. Secemsky, Akhilesh K. Sista, Leben Tefera, Ido Weinberg, Lauren M. Westafer, Michael N. Young
Read the Full Article on American Heart Association Journals
Stay updated with all scientific advances on Hemostasis Today.
-
Jul 5, 2026, 02:45Marie Luise Hütter-Krönke: Can a Short Course of BCMA-Targeted Therapy Induce Long-Term Remission in Refractory Autoimmune Disease?
-
Jul 5, 2026, 02:24Shreya Agarwa: Transforming Care For Adolescents With Heavy Menstrual Bleeding
-
Jul 4, 2026, 17:38Michael Stark: Greater Improvements in Cerebral Oxygenation With Restrictive Transfusion Thresholds
-
Jul 4, 2026, 17:27Reza Shojaei: How America Won the Plasma Race
-
Jul 4, 2026, 17:26Akshat Jain: The First CRISPR-Cas9 Gene Therapy Approved for Children as Young as 2 with SCD
-
Jul 4, 2026, 17:25Francesca Palandri: Dynamic, Treatment Response-Driven Risk Assessment in Polycythemia Vera
-
Jul 4, 2026, 17:24Thierry Burnouf: The Fragile Supply of Human Hyperimmune Immunoglobulins
-
Jul 4, 2026, 15:41Emmanuel J. Favaloro: New Research Highlights Benchmarks for Low Molecular Weight Heparin Monitoring
-
Jul 4, 2026, 15:38Roshni Kulkarni: Maternal Mortality In Bleeding Disorders